Additionally, high PTH levels, which are linked to secondary hyperparathyroidism in ESRD patients, have been reported in other studies to correlate with cancer risk through mechanisms involving bone turnover and chronic inflammatory processes. This evidence concerns the gene PTH and secondary hyperparathyroidism.